Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

PURPOSE: To determine the efficacy and toxicity of the combination of sorafenib, cytarabine, and idarubicin in patients with acute myeloid leukemia (AML) younger than age 65 years. PATIENTS AND METHODS: In the phase I part of the study, 10 patients with relapsed AML were treated with escalating dose...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ravandi, Farhad, Cortes, Jorge E., Jones, Daniel, Faderl, Stefan, Garcia-Manero, Guillermo, Konopleva, Marina Y., O'Brien, Susan, Estrov, Zeev, Borthakur, Gautam, Thomas, Deborah, Pierce, Sherry R., Brandt, Mark, Byrd, Anna, Bekele, B. Nebiyou, Pratz, Keith, Luthra, Rajyalakshmi, Levis, Mark, Andreeff, Michael, Kantarjian, Hagop M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2010
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2930809/
https://ncbi.nlm.nih.gov/pubmed/20212254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.4888
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak